Healthcare · Biotech & pharma
First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial
First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial
Oct 21 · 05:00GlobeNewswire
2,180 press releases in English indexed under biotech & pharma.
First Patient Treated in the C-FLASH-01 ConformalFLASH® Clinical Trial
Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra® and Restylane®, and pooled phase III study data for Relfydess® (relabotulinumtoxinA)1-8 With 30 years of innovation, Restylane continues to evolve through the devel
MARSEILLE, France, October 21, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company "), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in the following investor conferences: Stifel Healthcare Conference Dates: November 10–12, 2026 Location:
Austin, Texas and Abu Dhabi—Oct 20, 2026 Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, a
Austin, Texas and Abu Dhabi—Oct 20, 2026 Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, a
The metabolic dysfunction-associated steatohepatitis competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline MASH drugs, clinical strategies, upcoming therapeutics, and commercial analysis. The metabolic dysfunction-associated steatohepatitis competitive landscape report delivers important insights into approved as well as ongoing research on 200+ pipeline MASH drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
HOLLISTER, Calif., Oct. 20, 2026 -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of common stock in the offering are to be sold by Teknova. The offering is expected to close on or about October 22, 2026, subject to the satisfaction of customary closing conditions.
64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive care. More than 10 studies have been selected to highlight the latest findings on HER2- and HER3-targeted...
– Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month treatment with option of at-home administration after first dose – – CHB affects approximately 1.7 million people in the U.S. – CARLSBAD, Calif., October 21, 2026--Ionis Pharmaceutic
WATERTOWN, Mass., Oct. 20, 2026 -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of common stock at a public offering price of $75.00 per share. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Disc from this offering are expected to be $450 million, before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on October 22, 2026, subject to the satisfaction of customary closing conditions.
NEW YORK, Oct. 20, 2026 -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.